articleTop 1% cited
REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2
Transplantation · 1999 · Vol. 67(2) · pp. 276–284
Barry D. Kahan✉(Texas Medical Center)P. R. Rajagopalan(Medical University of South Carolina)Michael Hall(Novartis (Switzerland))
Abstract
Prophylactic basiliximab therapy is well tolerated, has an adverse event profile comparable to placebo, and significantly reduces the number of acute rejection episodes in renal allograft patients within the first year after transplantation.
Renal Transplantation Outcomes and TreatmentsCytomegalovirus and herpesvirus researchPolyomavirus and related diseasesBasiliximabMedicinePlaceboGastroenterologyInternal medicineUrologyCreatinineKidney transplantationTransplantationSurgery
MeSH terms
BasiliximabAcute DiseaseAdultAntibodies, MonoclonalCause of DeathCreatinineDouble-Blind MethodFemaleFollow-Up StudiesGraft RejectionHumansImmunosuppressive AgentsMaleMiddle AgedPostoperative Complications
Citations
482
FWCI
27.85
field-weighted impact
References
36
Percentile
100%
vs. same field & year
Citations per year
References
MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTS
Transplantation · 1995 · 1,382 citations
THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2
Transplantation · 1994 · 446 citations
A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1
Transplantation · 1996 · 1,061 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.